Hepatic Fibrosis Mechanisms and Diagnostics

Hepatic fibrosis arises from sustained liver injury of diverse aetiologies, including viral hepatitis, alcohol misuse and metabolic dysfunction. Central to its pathogenesis is the activation of hepatic stellate cells, which transdifferentiate into myofibroblast-like cells and secrete excessive extracellular matrix proteins, notably collagens I and III. This imbalance between fibrogenesis and fibrolysis progressively distorts normal hepatic architecture, leading to portal hypertension, impaired liver function and risk of cirrhosis or hepatocellular carcinoma. Early and accurate staging of fibrosis is critical, yet the current gold standard—liver biopsy—carries procedural risks and suffers sampling variability. Advances in non-invasive diagnostics now encompass circulating biomarkers reflecting matrix turnover, targeted imaging agents to visualise fibrotic deposits in situ and molecular scores integrating serum parameters. Such approaches promise to stratify risk, monitor therapeutic response and facilitate personalised management of chronic liver disease on a global scale.

Research from Nature Portfolio

Innovations in molecular MRI have yielded a protein-based contrast agent with high affinity for type I collagen, enabling detection of early-stage fibrosis and subtle heterogeneity within fibrotic nodules. This agent exhibits strong relaxivity at clinical field strengths, allowing dual-mode imaging of both collagen deposition and vascular remodelling associated with advanced disease. Separately, measurement of neo-epitope fragments of type III and VI collagen in serum has emerged as a direct marker of active fibrogenesis. One formation biomarker has demonstrated robust discrimination between mild and advanced fibrosis stages in nonalcoholic steatohepatitis cohorts, correlates with histological activity and declines following fibrosis regression, underscoring its potential utility in longitudinal monitoring.

Hepatic Fibrosis Mechanisms and Diagnostics publication trend

The graph below shows the total number of articles in hepatic fibrosis mechanisms and diagnostics across all publications each year (not limited to Nature Index journals).

Technical terms

Hepatic stellate cell: Perisinusoidal liver cell that, upon activation by injury, synthesises extracellular matrix and drives fibrogenesis.

Extracellular matrix (ECM): Network of structural proteins, glycoproteins and proteoglycans that provides tissue support; its excessive deposition underlies fibrosis.

Fibrogenesis: Process of new extracellular matrix formation, predominantly collagens, in response to chronic injury.

Relaxivity: Measure of a contrast agent’s efficacy in shortening nuclear magnetic resonance relaxation times, enhancing MRI signal.

PRO-C3: A serum biomarker representing the N-terminal propeptide of type III collagen, indicative of active collagen formation in liver fibrosis.

Metabolic dysfunction-associated steatotic liver disease (MASLD): A term reflecting fatty liver disease in the context of metabolic syndrome, superseding earlier nomenclature.

Nanomaterials: Engineered structures at the nanometre scale designed to improve targeting and imaging of fibrotic tissue.

References

1. Recent advances of nanomaterials in imaging liver fibrosis. BMEMat (2024).
2. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD. Current Obesity Reports (2024).
3. Early detection and staging of chronic liver diseases with a protein MRI contrast agent. Nature Communications (2019).
4. An Evaluation of the Collagen Fragments Related to Fibrogenesis and Fibrolysis in Nonalcoholic Steatohepatitis. Scientific Reports (2018).
5. Metabolic Signature of Hepatic Fibrosis: From Individual Pathways to Systems Biology. Cells (2019).
6. Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis. JHEP Reports (2021).